169 related articles for article (PubMed ID: 12810926)
1. Definition and treatment of lupus flares measured by the BILAG index.
Gordon C; Sutcliffe N; Skan J; Stoll T; Isenberg DA
Rheumatology (Oxford); 2003 Nov; 42(11):1372-9. PubMed ID: 12810926
[TBL] [Abstract][Full Text] [Related]
2. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
[TBL] [Abstract][Full Text] [Related]
3. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.
Lu TY; Ng KP; Cambridge G; Leandro MJ; Edwards JC; Ehrenstein M; Isenberg DA
Arthritis Rheum; 2009 Apr; 61(4):482-7. PubMed ID: 19333973
[TBL] [Abstract][Full Text] [Related]
4. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus.
Hay EM; Bacon PA; Gordon C; Isenberg DA; Maddison P; Snaith ML; Symmons DP; Viner N; Zoma A
Q J Med; 1993 Jul; 86(7):447-58. PubMed ID: 8210301
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus--a 5-yr prospective study.
Stoll T; Sutcliffe N; Mach J; Klaghofer R; Isenberg DA
Rheumatology (Oxford); 2004 Aug; 43(8):1039-44. PubMed ID: 15161983
[TBL] [Abstract][Full Text] [Related]
6. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus.
Isenberg DA; Rahman A; Allen E; Farewell V; Akil M; Bruce IN; D'Cruz D; Griffiths B; Khamashta M; Maddison P; McHugh N; Snaith M; Teh LS; Yee CS; Zoma A; Gordon C
Rheumatology (Oxford); 2005 Jul; 44(7):902-6. PubMed ID: 15814577
[TBL] [Abstract][Full Text] [Related]
7. Flares in pediatric systemic lupus erythematosus.
Weiss JE; Sison CP; Ilowite NT; Gottlieb BS; Eberhard BA
J Rheumatol; 2007 Jun; 34(6):1341-4. PubMed ID: 17477466
[TBL] [Abstract][Full Text] [Related]
8. Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group.
Wollaston SJ; Farewell VT; Isenberg DA; Gordon C; Merrill JT; Petri MA; Kalunian KC;
J Rheumatol; 2004 Dec; 31(12):2390-4. PubMed ID: 15570639
[TBL] [Abstract][Full Text] [Related]
9. Accurately describing changes in disease activity in Systemic Lupus Erythematosus.
Gladman DD; Urowitz MB; Kagal A; Hallett D
J Rheumatol; 2000 Feb; 27(2):377-9. PubMed ID: 10685800
[TBL] [Abstract][Full Text] [Related]
10. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER).
Merrill J; Buyon J; Furie R; Latinis K; Gordon C; Hsieh HJ; Brunetta P
Lupus; 2011 Jun; 20(7):709-16. PubMed ID: 21478286
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus.
Ward MM; Marx AS; Barry NN
J Rheumatol; 2000 Mar; 27(3):664-70. PubMed ID: 10743805
[TBL] [Abstract][Full Text] [Related]
12. Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission.
Wais T; Fierz W; Stoll T; Villiger PM
J Rheumatol; 2003 Oct; 30(10):2133-9. PubMed ID: 14528506
[TBL] [Abstract][Full Text] [Related]
13. Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus.
Gordon C; Wallace DJ; Shinada S; Kalunian KC; Forbess L; Braunstein GD; Weisman MH
Rheumatology (Oxford); 2008 Mar; 47(3):334-8. PubMed ID: 18238794
[TBL] [Abstract][Full Text] [Related]
14. The effect of menopause on disease activity in systemic lupus erythematosus.
Urowitz MB; Ibañez D; Jerome D; Gladman DD
J Rheumatol; 2006 Nov; 33(11):2192-8. PubMed ID: 16981295
[TBL] [Abstract][Full Text] [Related]
15. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.
Leandro MJ; Cambridge G; Edwards JC; Ehrenstein MR; Isenberg DA
Rheumatology (Oxford); 2005 Dec; 44(12):1542-5. PubMed ID: 16188950
[TBL] [Abstract][Full Text] [Related]
16. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus.
Ng KP; Manson JJ; Rahman A; Isenberg DA
Arthritis Rheum; 2006 Dec; 55(6):900-4. PubMed ID: 17139667
[TBL] [Abstract][Full Text] [Related]
17. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus.
Marto N; Bertolaccini ML; Calabuig E; Hughes GR; Khamashta MA
Ann Rheum Dis; 2005 Mar; 64(3):444-8. PubMed ID: 15286009
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation.
Gladman DD; Goldsmith CH; Urowitz MB; Bacon P; Bombardier C; Isenberg D; Kalunian K; Liang MH; Maddison P; Nived O
J Rheumatol; 1994 Aug; 21(8):1468-71. PubMed ID: 7983648
[TBL] [Abstract][Full Text] [Related]
19. Role of specialty care in the management of patients with systemic lupus erythematosus.
Urowitz MB; Kagal A; Rahman P; Gladman DD
J Rheumatol; 2002 Jun; 29(6):1207-10. PubMed ID: 12064836
[TBL] [Abstract][Full Text] [Related]
20. How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index.
Thanou A; Chakravarty E; James JA; Merrill JT
Rheumatology (Oxford); 2014 Dec; 53(12):2175-81. PubMed ID: 24729400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
